Clinical Trial: NCT06403436
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | TOLREMO therapeutics AG |
| Information Provided By: | TOLREMO therapeutics AG |
| Last Update Posted: | 2026-07-07 |
Study Overview
Brief Summary
The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
Official Title
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Conditions
Advanced Solid Tumor, Adult Solid Tumor, Adult Disease, Cancer, NSCLC, EGFR, KRAS G12C, Squamous Cell Lung Cancer
Intervention / Treatment
- Drug: TT125-802
Other Study ID Numbers
- TT-CSP-001
Start Date (Actual)
2023-11-07
Primary Completion Date (Actual)
2026-06-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
45
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | TOLREMO therapeutics AG |
| Information Provided By: | TOLREMO therapeutics AG |
| Last Update Posted: | 2026-07-07 |
Study Overview
Brief Summary
The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
Official Title
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Conditions
Advanced Solid Tumor, Adult Solid Tumor, Adult Disease, Cancer, NSCLC, EGFR, KRAS G12C, Squamous Cell Lung Cancer
Intervention / Treatment
- Drug: TT125-802
Other Study ID Numbers
- TT-CSP-001
Start Date (Actual)
2023-11-07
Primary Completion Date (Actual)
2026-06-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
45
Study Type
Interventional
Phase
Phase 1